SILICON LABORATORIES INC.
$221.43
−0.69 (−0.31%) · delayed · Nov 13, 2026
Five-year price
52w $115.51 to $223.50
- Market cap
- $7.4B
- Enterprise value
- $7.0B
- P/E
- —
- EV / EBIT
- —
- FCF yield
- 0.9%
- ROIC
- −7.6%
- Debt / equity
- —
- Piotroski F
- 6/9
Value scorecard · FY2025
Does it pass the value tests?
Quality
50
- ○ROIC > 12% (5y avg)5y avg ROIC -3.8%
- ●ROE > 15% (5y avg)5y avg ROE 15.1%
- ○Stable operating marginsMargin volatility 12.9% (σ, 5y)
- ○Earnings convert to cashFCF / net income 64% (5y avg)
- ●Growing revenueRevenue CAGR 5y 9.0%
- ●Shrinking share countDiluted shares -26.3% over 5y
Value
n/a
- –P/E below 15P/E n/a
- –EV/EBIT below 12EV/EBIT n/a
- ○FCF yield above 6%FCF yield 0.9%
- –Price below Graham NumberGraham Number n/a
- ○P/B below 3P/B 6.8
Safety
50
- –Debt / equity below 0.5D/E n/a
- ○Debt payable in < 4 yrs of earningsNet debt $-0.4B
- ○Interest coverage > 8xCoverage -72.3x
- ●Current ratio > 1.5Current ratio 4.69
- ●Piotroski F-score ≥ 6F-score 6/9
Graham Defensive
20
- ○Adequate size (revenue > $2B)Revenue $0.8B
- ●Strong condition (current ratio ≥ 2)Current ratio 4.69
- ○Earnings stability (no loss, 10y)10 years of data
- ○Uninterrupted dividendsDividends paid every year on record
- ○Earnings growth ≥ 33% (10y, 3y avgs)EPS growth -303%
- –Moderate P/E (≤ 15 on 3y avg EPS)P/E (3y avg) n/a
- –P/E × P/B ≤ 22.5Product n/a
Valuation lab
What do you have to believe?
At $221.43, the market is pricing in about 28.2% annual free-cash-flow growth for the next decade (9% discount rate, 2.5% terminal growth).
Starting cash flow
Net debt −$364M · 33M shares · 5y revenue CAGR 9.0%
Intrinsic value
$61.69
Price
$221.43
Premium paid
259%
What the price implies
The market is paying for 28.2% annual cash-flow growth for 10 years at a 9.0% discount rate.
Terminal value share
61% of the value sits beyond year 10.
Financial statements
A decade of the record.
USD millions · fiscal years · source: SEC 10-K XBRL
| Line item | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 698 | 769 | 868 | 474 | 511 | 721 | 1,024 | 782 | 584 | 785 |
| Gross profit | 422 | 454 | 521 | 280 | 295 | 425 | 643 | 461 | 312 | 457 |
| Operating income | 66 | 85 | 85 | (89) | (107) | (33) | 119 | (24) | (165) | (71) |
| Operating margin | 9.5% | 11.1% | 9.8% | -18.7% | -21.0% | -4.6% | 11.6% | -3.1% | -28.3% | -9.0% |
| Pre-tax income | 64 | 77 | 72 | (96) | (130) | (44) | 130 | (27) | (155) | (58) |
| Income tax | 3 | 30 | (11) | 7 | (15) | 13 | 38 | 8 | 36 | 7 |
| Net income | 61 | 47 | 84 | 19 | 13 | 2,117 | 91 | (35) | (191) | (65) |
| EPS (diluted) | 1.45 | 1.09 | 1.90 | 0.43 | 0.28 | 47.78 | 2.54 | -1.09 | -5.93 | -1.98 |
| Diluted shares | 42 | 43 | 44 | 44 | 44 | 44 | 36 | 32 | 32 | 33 |
Who owns it
Superinvestors
Filings wire